I was delighted to be contacted by ITM AG, a Germany based pharmaceutical company specialising in targeted radionuclide technology in precision oncology (e.g. Peptide Receptor Radionuclide Therapy – PRRT). The company is formally known as ITM Isotopen Technologien München.
One of their pipeline developments is 177Lu-Edotreotide / Solucin® in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET). The development is via the COMPETE Phase III Clinical Trial which is being conducted worldwide in 11 countries at 33 sites and is open for recruitment. I actually wrote about this trial after attending a workshop at the annual ENETS conference in 2018.
I was delighted when they wanted to interview me to see how I was coping 2 years on and particularly during COVID-19.
I embedded the PDF file of the interview below but in case you’re reading on a small device, you can find the file by clicking here.
The original article “I’m still here” can be found here or click the picture
Disclaimer. Ronny Allan has received no financial payment from ITM AG and the interview or this article does not constitute a recommendation to use any of their products. Furthermore, taking part in a clinical trial is a big decision and must be considered carefully in conjunction with your healthcare professionals and close family.
Thanks for reading
I’m also active on Facebook. Like my page for even more news. I’m also building up this site here: Ronny Allan
My Diagnosis and Treatment History
Sign up for my twitter newsletter
Read my Cure Magazine contributions
Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts to your email.
Great article! And the approach may be of value for other tumours, such as thymomas. Cheers David